Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 421
Filtrar
1.
Biol Pharm Bull ; 44(3): 442-447, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33642553

RESUMO

The dopamine system plays an important role in regulating many brain functions, including the motor function. The blockade of dopamine receptors results in a serious motor dysfunction, such as catalepsy and Parkinsonism. However, the neuronal mechanism underlying the drug-induced motor dysfunction is not well understood. Here, we examine brain-wide activation patterns in Fos-enhanced green fluorescent protein reporter mice that exhibit cataleptic behavior induced by SCH39166, a dopamine D1-like receptor antagonist, and raclopride, a dopamine D2-like receptor antagonist. Support vector classifications showed that the orbital cortex (ORB) and striatum including the caudoputamen (CP) and nucleus accumbens (ACB), prominently contribute to the discrimination between brains of the vehicle-treated and both SCH39166- and raclopride-treated mice. Interregional correlations indicated that the increased functional connectivity of functional networks, including the ORB, CP, and ACB, is the common mechanism underlying SCH39166- and raclopride-induced cataleptic behavior. Moreover, the distinct mechanisms in the SCH39166- and raclopride-induced cataleptic behaviors are the decreased functional connectivity between three areas above and the cortical amygdala, and between three areas above and the anterior cingulate cortex, respectively. Thus, the alterations of functional connectivity in diverse brain regions, including the ORB, provide new insights on the mechanism underlying drug-induced movement disorders.


Assuntos
Benzazepinas/farmacologia , Catalepsia/induzido quimicamente , Corpo Estriado/efeitos dos fármacos , Antagonistas de Dopamina/farmacologia , Córtex Pré-Frontal/efeitos dos fármacos , Racloprida/farmacologia , Animais , Catalepsia/fisiopatologia , Corpo Estriado/fisiologia , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Córtex Pré-Frontal/fisiologia , Receptores de Dopamina D1/antagonistas & inibidores , Receptores de Dopamina D1/fisiologia , Receptores de Dopamina D2/fisiologia
2.
Proc Natl Acad Sci U S A ; 114(17): E3526-E3535, 2017 04 25.
Artigo em Inglês | MEDLINE | ID: mdl-28396432

RESUMO

Narcolepsy is a sleep disorder caused by the loss of orexin (hypocretin)-producing neurons and marked by excessive daytime sleepiness and a sudden weakening of muscle tone, or cataplexy, often triggered by strong emotions. In a mouse model for narcolepsy, we previously demonstrated that serotonin neurons of the dorsal raphe nucleus (DRN) mediate the suppression of cataplexy-like episodes (CLEs) by orexin neurons. Using an optogenetic tool, in this paper we show that the acute activation of DRN serotonin neuron terminals in the amygdala, but not in nuclei involved in regulating rapid eye-movement sleep and atonia, suppressed CLEs. Not only did stimulating serotonin nerve terminals reduce amygdala activity, but the chemogenetic inhibition of the amygdala using designer receptors exclusively activated by designer drugs also drastically decreased CLEs, whereas chemogenetic activation increased them. Moreover, the optogenetic inhibition of serotonin nerve terminals in the amygdala blocked the anticataplectic effects of orexin signaling in DRN serotonin neurons. Taken together, the results suggest that DRN serotonin neurons, as a downstream target of orexin neurons, inhibit cataplexy by reducing the activity of amygdala as a center for emotional processing.


Assuntos
Tonsila do Cerebelo , Catalepsia , Núcleo Dorsal da Rafe , Neurônios Serotoninérgicos/metabolismo , Transdução de Sinais , Tonsila do Cerebelo/metabolismo , Tonsila do Cerebelo/patologia , Tonsila do Cerebelo/fisiopatologia , Animais , Catalepsia/genética , Catalepsia/metabolismo , Catalepsia/patologia , Catalepsia/fisiopatologia , Núcleo Dorsal da Rafe/metabolismo , Núcleo Dorsal da Rafe/patologia , Núcleo Dorsal da Rafe/fisiopatologia , Movimentos Oculares , Masculino , Camundongos , Camundongos Knockout , Neurônios Serotoninérgicos/patologia , Serotonina/metabolismo
3.
Int J Mol Sci ; 21(10)2020 May 12.
Artigo em Inglês | MEDLINE | ID: mdl-32408504

RESUMO

Dual target ligands are a promising concept for the treatment of Parkinson's disease (PD). A combination of monoamine oxidase B (MAO B) inhibition with histamine H3 receptor (H3R) antagonism could have positive effects on dopamine regulation. Thus, a series of twenty-seven 4-tert-butylphenoxyalkoxyamines were designed as potential dual-target ligands for PD based on the structure of 1-(3-(4-tert-butylphenoxy)propyl)piperidine (DL76). Probed modifications included the introduction of different cyclic amines and elongation of the alkyl chain. Synthesized compounds were investigated for human H3R (hH3R) affinity and human MAO B (hMAO B) inhibitory activity. Most compounds showed good hH3R affinities with Ki values below 400 nM, and some of them showed potent inhibitory activity for hMAO B with IC50 values below 50 nM. However, the most balanced activity against both biological targets showed DL76 (hH3R: Ki = 38 nM and hMAO B: IC50 = 48 nM). Thus, DL76 was chosen for further studies, revealing the nontoxic nature of DL76 in HEK293 and neuroblastoma SH-SY5Ycells. However, no neuroprotective effect was observed for DL76 in hydrogen peroxide-treated neuroblastoma SH-SY5Y cells. Furthermore, in vivo studies showed antiparkinsonian activity of DL76 in haloperidol-induced catalepsy (Cross Leg Position Test) at a dose of 50 mg/kg body weight.


Assuntos
Aminas/farmacologia , Antagonistas dos Receptores Histamínicos H3/farmacologia , Inibidores da Monoaminoxidase/farmacologia , Monoaminoxidase/metabolismo , Aminas/química , Animais , Catalepsia/induzido quimicamente , Catalepsia/fisiopatologia , Catalepsia/prevenção & controle , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Células HEK293 , Haloperidol , Antagonistas dos Receptores Histamínicos H3/química , Humanos , Cinética , Ligantes , Masculino , Estrutura Molecular , Inibidores da Monoaminoxidase/química , Doença de Parkinson/fisiopatologia , Doença de Parkinson/prevenção & controle , Ratos Wistar , Relação Estrutura-Atividade
4.
Pak J Pharm Sci ; 33(5): 1945-1953, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33824100

RESUMO

We determined anti-Parkinson's activity of M. chamomilla L. tea in chlorpromazine (CPZ) developed investigational animal model. In this research, effects of M. chamomilla L. tea 2.14ml/ kg P.O were studied on cataleptic behavior and its effect on brain histopathological changes and immunohistochemistry (IHC) in rats. The experimental design was developed by administering CPZ (3mg/kg, I/P) for twenty-one days to produce Parkinson's disease-like symptoms to 4 animal groups. We observed that chlorpromazine significantly produced motor dysfunctions (catalepsy) in a time period of twenty-one days. The M. chamomilla L. significantly (P<0.005) minimized/shorten/taper down catalepsy in rats just like standard group (Levodopa/carbidopa treated group). The maximum reduction was observed from both treated and standard groups on the 21st day. M. chamomilla L. treated rats mid brain sections showed presence of proliferative blood vessels, increase cellularity with reactive glial cells as compared to CPZ group. Furthermore, immunostaining CD68 & CD21 of M. chamomilla L. treated rats mid brain region showed few CD68 cells & no polymorphs neutrophils after CD21 staining. Thus, this research work disclosed the neuroprotective effect of M. chamomilla L. tea against Parkinson's disease-like symptoms or anti-Parkinson's activity induced by CPZ.


Assuntos
Antiparkinsonianos/farmacologia , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Catalepsia/prevenção & controle , Matricaria , Atividade Motora/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Transtornos Parkinsonianos/prevenção & controle , Extratos Vegetais/farmacologia , Animais , Antiparkinsonianos/isolamento & purificação , Encéfalo/metabolismo , Encéfalo/patologia , Encéfalo/fisiopatologia , Catalepsia/induzido quimicamente , Catalepsia/patologia , Catalepsia/fisiopatologia , Clorpromazina , Modelos Animais de Doenças , Masculino , Matricaria/química , Fármacos Neuroprotetores/isolamento & purificação , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/patologia , Transtornos Parkinsonianos/fisiopatologia , Extratos Vegetais/isolamento & purificação , Ratos Wistar
5.
Behav Pharmacol ; 30(2 and 3-Spec Issue): 229-238, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30632994

RESUMO

Catalepsy - an immobile state in which individuals fail to change imposed postures - can be induced by haloperidol. In rats, the pattern of haloperidol-induced catalepsy is very similar to that observed in Parkinson's disease (PD). As some PD symptoms seem to depend on the patient's emotional state, and as anxiety disorders are common in PD, it is possible that the central mechanisms regulating emotional and cataleptic states interplay. Previously, we showed that haloperidol impaired contextual-induced alarm calls in rats, without affecting footshock-evoked calls. Here, we evaluated the influence of distinct aversive stimulations on the haloperidol-induced catalepsy. First, male Wistar rats were subjected to catalepsy tests to establish a baseline state after haloperidol or saline administration. Next, distinct cohorts were exposed to open-field; elevated plus-maze; open-arm confinement; inescapable footshocks; contextual conditioned fear; or corticosterone administration. Subsequently, catalepsy tests were performed again. Haloperidol-induced catalepsy was verified in all drug-treated animals. Exposure to open-field, elevated plus-maze, open-arm confinement, footshocks, or administration of corticosterone had no significant effect on haloperidol-induced catalepsy. Contextual conditioned fear, which is supposed to promote a more intense fear, increased catalepsy over time. Our findings suggest that only specific defensive circuitries modulate the nigrostriatal system mediating the haloperidol-induced cataleptic state.


Assuntos
Afeto/efeitos dos fármacos , Catalepsia/fisiopatologia , Medo/efeitos dos fármacos , Animais , Comportamento Animal/efeitos dos fármacos , Condicionamento Clássico/efeitos dos fármacos , Modelos Animais de Doenças , Antagonistas de Dopamina/farmacologia , Haloperidol/farmacologia , Masculino , Doença de Parkinson/metabolismo , Ratos , Ratos Wistar
6.
Bull Exp Biol Med ; 168(2): 300-303, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31776950

RESUMO

Phenotypical study was carried out in rats with pendulum movements. The animals exhibited a high level of abortive seizures in response to audiogenic stimuli and longer postictal catalepsy in comparison with those in Wistar population. Seizure severity positively correlated with the duration of poststimulus catalepsy (r=0.90). High aggressiveness towards humans, the absence of BP elevation in stress, lower body weights, and lower weights of the kidneys and spleen in PM rats are considered concomitant traits. Correlations were detected between startle-1 and BP in rats with pendulum movements (r=0.70) and between startle-10 and BP in narcotized Wistar rats (r=-0.0.71). The newly described signs in rats with pendulum movements did not contradict the signs of the focal seizure model with typical automatisms in humans.


Assuntos
Automatismo/fisiopatologia , Reflexo de Sobressalto/fisiologia , Convulsões/patologia , Estimulação Acústica , Animais , Pressão Sanguínea/fisiologia , Catalepsia/fisiopatologia , Rim/fisiopatologia , Movimento/fisiologia , Ratos , Ratos Wistar , Baço/fisiopatologia
7.
Pharmacol Res ; 121: 1-13, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28414178

RESUMO

The effects of antipsychotic drugs (APDs) on the adolescent brain are poorly understood despite a dramatic increase in prescription of these drugs in adolescents over the past twenty years. Neuronal systems continue to be remodeled during adolescence. Therefore, when given in adolescence, antipsychotic drugs (APDs) have the potential to affect this remodeling. In this study we investigated the effects of chronic 22-day risperidone treatment (1.3mg/kg/day) in both adolescent and adult rats. We examined short- and long-term changes in behaviour (catalepsy, locomotion and conditioned avoidance response (CAR)), and dopaminergic and serotonergic neurochemistry in the striatum and the nucleus accumbens. Here, we report that, both during chronic treatment and after a lengthy drug-free interval, risperidone induced a sensitised cataleptic response regardless of the age of exposure. Selectively in adolescents, risperidone-induced catalepsy was inversely correlated with striatal dopamine turnover immediately after chronic treatment. After a drug-free interval, a significant proportion of rats with prior adolescent risperidone treatment also failed to acquire CAR to a defined criterion. Our data provide evidence that the same chronic risperidone treatment regimen can induce contrasting short- and long-term neural outcomes in the adolescent and adult brains.


Assuntos
Antipsicóticos/efeitos adversos , Catalepsia/induzido quimicamente , Risperidona/efeitos adversos , Fatores Etários , Animais , Antipsicóticos/administração & dosagem , Monoaminas Biogênicas/análise , Monoaminas Biogênicas/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/crescimento & desenvolvimento , Encéfalo/metabolismo , Encéfalo/fisiopatologia , Catalepsia/sangue , Catalepsia/metabolismo , Catalepsia/fisiopatologia , Corticosterona/sangue , Dopamina/metabolismo , Locomoção/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-Dawley , Risperidona/administração & dosagem
8.
J Biochem Mol Toxicol ; 30(7): 360-9, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27252111

RESUMO

Autophagy is necessary for neuronal homeostasis and its dysfunction has been implicated in Parkinson's disease (PD) as it can exacerbate endoplasmic reticulum (ER) stress and ER stress-induced apoptosis. Quercetin is a flavonoid known for its neuroprotective and antioxidant effects. The present study investigated the protective, autophagy-modulating effects of quercetin in the rotenone rat model of PD. Rotenone was intraperitoneally injected at dose of 2 ml/kg/day for 4 weeks. Simultaneous intraperitoneal injection of quercetin was given at a dose of 50 mg/kg/day also for 4 weeks. Neurobehavioral changes were studied. Oxidative/antioxidant status, C/EBP homologous protein (CHOP), Beclin-1, and dopamine levels were assessed. DNA fragmentation and histopathological changes were evaluated. This research work revealed that quercetin significantly attenuated rotenone-induced behavioral impairment, augmented autophagy, ameliorated ER stress- induced apoptosis with attenuated oxidative stress. From the current study, quercetin can act as an autophagy enhancer in PD rat model and modulates the microenvironment that leads to neuronal death.


Assuntos
Antioxidantes/farmacologia , Autofagia/efeitos dos fármacos , Catalepsia/tratamento farmacológico , Disfunção Cognitiva/tratamento farmacológico , Fármacos Neuroprotetores/farmacologia , Transtornos Parkinsonianos/tratamento farmacológico , Quercetina/farmacologia , Animais , Proteína Beclina-1/genética , Proteína Beclina-1/metabolismo , Peso Corporal/efeitos dos fármacos , Catalepsia/induzido quimicamente , Catalepsia/genética , Catalepsia/fisiopatologia , Disfunção Cognitiva/induzido quimicamente , Disfunção Cognitiva/genética , Disfunção Cognitiva/fisiopatologia , Dopamina/metabolismo , Retículo Endoplasmático/efeitos dos fármacos , Retículo Endoplasmático/metabolismo , Retículo Endoplasmático/patologia , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Regulação da Expressão Gênica , Injeções Intraperitoneais , Masculino , Estresse Oxidativo , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/genética , Transtornos Parkinsonianos/fisiopatologia , Ratos , Rotenona , Transdução de Sinais , Tiorredoxina Dissulfeto Redutase/genética , Tiorredoxina Dissulfeto Redutase/metabolismo , Fator de Transcrição CHOP/genética , Fator de Transcrição CHOP/metabolismo
9.
Acta Pol Pharm ; 73(2): 529-35, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27180446

RESUMO

The present study was undertaken to evaluate the possible protective effect of thymoquinone on chlorpromazine induced catalepsy, locomotor activity and cerebral oxidative stress in rats. The rats were divided into four groups, each group containing eight animals. The animals were evaluated after repeated administration of chlorpromazine (CPZ) 30 min before the administration of thymoquinone (TQ) for 21 days. Catalepsy was assessed using block method whereas the locomotor activity was assessed using acceleratory rotarod and actophotometer. Markers of oxidative stress parameters (LPO, GSH, GPx, GR, GST and CAT) were evaluated in the brain of rats. The cataleptic scores were significantly increased in CPZ treated rats when compared with normal control rats. Oral administration of TQ (5 and 10 mg/kg) significantly decreased cataleptic scores when compared with chlorpromazine (CPZ) treated rats. The muscle coordination and spontaneous locomotor activity was significantly decreased in CPZ treated rats when compared with normal control rats. Treatment with TQ significantly improved the muscle coordination and spontaneous locomotor activity when compared with CPZ treated rats. TQ treated rats significantly reduced the elevated levels of lipid peroxidation (LPO), increased levels of antioxidant enzymes i.e., reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST) and catalase (CAT) when compared with CPZ treated rats. The results clearly suggest that supplementation with TQ can be used to preclude CPZ induced extrapyramidal side effects and may find a role in reducing the oxidative stress.


Assuntos
Antioxidantes/farmacologia , Comportamento Animal/efeitos dos fármacos , Benzoquinonas/farmacologia , Encéfalo/efeitos dos fármacos , Catalepsia/tratamento farmacológico , Clorpromazina , Atividade Motora/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Animais , Biomarcadores/metabolismo , Encéfalo/metabolismo , Encéfalo/fisiopatologia , Catalepsia/induzido quimicamente , Catalepsia/metabolismo , Catalepsia/fisiopatologia , Modelos Animais de Doenças , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Ratos Wistar , Teste de Desempenho do Rota-Rod
10.
Pak J Pharm Sci ; 29(5): 1525-1529, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27731807

RESUMO

Potential roles of natural products have been identified for preventing or treating various diseases. Our aim was to investigate the effectiveness of camel milk in an animal model of Parkinson's disease and compare it with standard treatment (levodopa + carbidopa combination). 40 Wistar albino rats weighing 200-250 gram were divided into four groups of 10 animals each. Group I was kept on water and served as normal control, group II served as negative control, treated with chlorpromazine (5mg/kg i.p.), group III was given camel milk (33ml/kg p.o) and group IV the standard combination of levodopa + carbidopa (100+10mg/kg) respectively, 30 minutes after chlorpromazine treatment. All animals were subjected to the drugs treatment for 30 days. Catalepsy was assessed by Bar test on day 21 and day 30 at 30, 60, 90 and 120 minutes interval. On 30th day animals were sacrificed and whole brains were examined for histopathological changes. The results revealed highly significant (p<0.001) anti-cataleptic effect of camel milk on day 21 and 30 in comparison to chlorpromazine. When compared with standard therapy, the results showed that anti-Parkinson's activity of camel milk was significant (p<0.01) on day 21. However, the difference in activity was non-significant on day 30. Histopathology of the brain showed that administration of camel milk reveals intact architecture with mild degenerative changes than chlorpromazine and levodopa + carbidopa treated animals. In conclusion, camel milk possesses anti-Parkinson's activity. However, its long term efficacy and safety needs to be evaluated clinically.


Assuntos
Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Camelus , Clorpromazina , Leite , Transtornos Parkinsonianos/prevenção & controle , Animais , Antiparkinsonianos/farmacologia , Encéfalo/patologia , Encéfalo/fisiopatologia , Carbidopa/farmacologia , Catalepsia/induzido quimicamente , Catalepsia/patologia , Catalepsia/fisiopatologia , Catalepsia/prevenção & controle , Combinação de Medicamentos , Feminino , Levodopa/farmacologia , Masculino , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/patologia , Transtornos Parkinsonianos/psicologia , Ratos Wistar , Fatores de Tempo
11.
Neurobiol Dis ; 82: 342-348, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26206409

RESUMO

Non-motor symptoms of Parkinson's disease are under-studied and therefore not well treated. Here, we investigated the role of combined depletions of dopamine, norepinephrine and/or serotonin in the manifestation of motor and non-motor deficits in the rat. Then, we studied the impact of these depletions on the efficacy of deep brain stimulation of the subthalamic nucleus (STN-DBS). We performed selective depletions of dopamine, norepinephrine and serotonin, and the behavioral effects of different combined depletions were investigated using the open field, the elevated plus maze and the forced swim test. Bilateral dopamine depletion alone induced locomotor deficits associated with anxiety and mild "depressive-like" behaviors. Although additional depletions of norepinephrine and/or serotonin did not potentiate locomotor and anxiety disorders, combined depletions of the three monoamines dramatically exacerbated "depressive-like" behavior. STN-DBS markedly reversed locomotor deficits and anxiety behavior in animals with bilateral dopamine depletion alone. However, these improvements were reduced or lost by the additional depletion of norepinephrine and/or serotonin, indicating that the depletion of these monoamines may interfere with the antiparkinsonian efficacy of STN-DBS. Furthermore, our results showed that acute STN-DBS improved "depressive-like" disorder in animals with bilateral depletion of dopamine and also in animals with combined depletions of the three monoamines, which induced severe immobility in the forced swim test. Our data highlight the key role of monoamine depletions in the pathophysiology of anxiety and depressive-like disorders and provide the first evidence of their negative consequences on the efficacy of STN-DBS upon the motor and anxiety disorders in the context of Parkinson's disease.


Assuntos
Monoaminas Biogênicas/metabolismo , Estimulação Encefálica Profunda , Dopamina/deficiência , Transtornos Parkinsonianos/fisiopatologia , Transtornos Parkinsonianos/terapia , Núcleo Subtalâmico/metabolismo , Animais , Transtornos de Ansiedade/fisiopatologia , Transtornos de Ansiedade/terapia , Benzilaminas , Catalepsia/fisiopatologia , Catalepsia/terapia , Corpo Estriado/metabolismo , Estimulação Encefálica Profunda/métodos , Transtorno Depressivo/fisiopatologia , Transtorno Depressivo/terapia , Lobo Frontal/metabolismo , Masculino , Atividade Motora/fisiologia , Oxidopamina , Transtornos Parkinsonianos/psicologia , Ratos Sprague-Dawley
12.
Artigo em Russo | MEDLINE | ID: mdl-25966577

RESUMO

Behavioral effects of classic antidepressants, fluoxetine and imipramine, and new psychotropic benzopentathiepin TC-2153 (20 mg/kg, per os) were studied on mice differing in the predisposition to catalepsy-noncataleptic AKR strain and cataleptic strains CBA and AKR.CBA-D13Mit76 (D13). Mice of D13 strain was created by transferring the CBA-allele of major locus of catalepsy to AKR genome. In the forced swim test (FST) fluoxetine showed antidepressant effect on mice of all three strains, imipramine was effective only in D13 mice, while TC-2153 produced antidepressant effect on AKR and D13 mice. Unlike to imipramine and fluoxetine, TC-2153 did not produce negative side effects in the open field and elevated plus-maze tests. Thus, TC-2153 produces antidepressant effects similar to imipramine and fluoxetine, without any visible negative side effect on locomotory activity and anxiety. The D13 mice in the FST showed high sensitivity to the studied drugs in comparison to the parent strains and can be used as new genetic model for investigation of the mechanism of antidepressant effects.


Assuntos
Antidepressivos/administração & dosagem , Ansiedade/tratamento farmacológico , Catalepsia/tratamento farmacológico , Predisposição Genética para Doença , Animais , Ansiedade/genética , Ansiedade/fisiopatologia , Benzotiepinas/administração & dosagem , Catalepsia/genética , Catalepsia/fisiopatologia , Fluoxetina/administração & dosagem , Genótipo , Humanos , Imipramina/administração & dosagem , Camundongos
13.
Artigo em Russo | MEDLINE | ID: mdl-25975144

RESUMO

Catalepsy usually is caused by imbalance of dopamine (DA) and serotonin (5-HT) systems of brain. The aim of our work was to verify if this imbalance plays an important role in the mechanism of hereditary catalepsy in mice. Maintenance of DA, 5-HT and their main metabolites--5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylacetic acid, homovanilic acid was determined in cortex, hypothalamus, hippocampus, striatum, substantia nigra and nuclei raphes in catalepsy-resistant AKR/J mice strain and catalepsy-prone CBA/LacJ mice strain and recombinant mice AKR/J.CBA-D13Mit76 (D13) strain. The latest strain was selected by transferring of a fragment of the chromosome 13 from CBA/LacJ carrying the main gene of hereditary catalepsy to AKR/J genome. There were no interstrain differences in concentration of biogenic amines and their metabolites in all brain regions. As a result of our work the hypothesis about the important role of 5-HT and/or DA systems of brain in the mechanism of hereditary catalepsy in mice was denied.


Assuntos
Ácido 3,4-Di-Hidroxifenilacético/metabolismo , Catalepsia/metabolismo , Dopamina/metabolismo , Ácido Homovanílico/metabolismo , Ácido Hidroxi-Indolacético/metabolismo , Serotonina/metabolismo , Animais , Catalepsia/genética , Catalepsia/fisiopatologia , Córtex Cerebral/metabolismo , Córtex Cerebral/fisiopatologia , Corpo Estriado/metabolismo , Corpo Estriado/fisiopatologia , Cruzamentos Genéticos , Predisposição Genética para Doença , Hipocampo/metabolismo , Hipocampo/fisiopatologia , Hipotálamo/metabolismo , Hipotálamo/fisiopatologia , Masculino , Camundongos Endogâmicos AKR , Camundongos Endogâmicos CBA , Núcleo Accumbens/metabolismo , Núcleo Accumbens/fisiopatologia , Núcleo Magno da Rafe/metabolismo , Núcleo Magno da Rafe/fisiopatologia , Substância Negra/metabolismo , Substância Negra/fisiopatologia
14.
Neurosciences (Riyadh) ; 19(2): 100-5, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24739405

RESUMO

OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia. METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: amphetamine-free (control), amphetamine, 50, and 100 mg/kg DHEA. The DHEA was administered intraperitoneally (ip) for 5 days. Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia. The study was conducted at the Animal Experiment Laboratories, Department of Pharmacology, Medical School, Eskisehir Osmangazi University, Eskisehir, Turkey between March and May 2012. Statistical analysis was carried out using Kruskal-Wallis test for hyper locomotion, and one-way ANOVA for climbing and catalepsy tests. RESULTS: In the amphetamine-induced locomotion test, there were significant increases in all movements compared with the amphetamine-free group. Both DHEA 50 mg/kg (p<0.05), and 100 mg/kg (p<0.01) significantly decreased all movements compared with the amphetamine-induced locomotion group. There was a significant difference between groups in the haloperidol-induced catalepsy test (p<0.05). There was no significant difference between groups in terms of total climbing time in the apomorphine-induced climbing test (p>0.05). CONCLUSION: We observed that DHEA reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior. We suggest that DHEA displays typical neuroleptic-like effects, and may be used in the treatment of schizophrenia.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Anfetamina/toxicidade , Estimulantes do Sistema Nervoso Central/toxicidade , Desidroepiandrosterona/uso terapêutico , Esquizofrenia/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Animais , Apomorfina , Catalepsia/induzido quimicamente , Catalepsia/fisiopatologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Locomoção/efeitos dos fármacos , Camundongos , Esquizofrenia/fisiopatologia , Estatísticas não Paramétricas , Fatores de Tempo
15.
J Pharmacol Exp Ther ; 347(3): 542-6, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24030013

RESUMO

Repeated haloperidol treatment administered to nonhuman primates (NHPs) over several months or even years leads to the gradual appearance of drug-induced dystonic reactions in the orofacial region (mouth opening, tongue protrusion or retraction, bar biting) and in the whole body (writhing of the limbs and trunk, bar grasping). The propensity of antipsychotics to induce dystonia in NHPs is not correlated with their propensity to induce catalepsy in rodents, suggesting that the two types of effects are dissociated and may represent distinct aspects of the extrapyramidal symptoms induced by antipsychotics. In view of the clear homology to clinically observed phenomena, antipsychotic-induced dystonias in antipsychotic-primed NHPs would appear to possess a high degree of translational validity. These NHP phenomena could therefore serve as a useful model for predicting the occurrence of similar abnormal movements with novel substances developed for the treatment of schizophrenia or other psychotic disorders. Moreover, the NHP dystonia model could possibly serve as a biomarker for substances that will eventually cause tardive dyskinesia in patients.


Assuntos
Antipsicóticos/efeitos adversos , Discinesia Induzida por Medicamentos/fisiopatologia , Primatas/fisiologia , Animais , Catalepsia/induzido quimicamente , Catalepsia/fisiopatologia , Modelos Animais de Doenças , Distonia/induzido quimicamente , Distonia/fisiopatologia , Doença de Parkinson Secundária/induzido quimicamente , Doença de Parkinson Secundária/fisiopatologia , Agitação Psicomotora/fisiopatologia , Ratos
16.
Proc Natl Acad Sci U S A ; 107(33): 14845-50, 2010 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-20682746

RESUMO

The direct and indirect pathways of the basal ganglia have been proposed to oppositely regulate locomotion and differentially contribute to pathological behaviors. Analysis of the distinct contributions of each pathway to behavior has been a challenge, however, due to the difficulty of selectively investigating the neurons comprising the two pathways using conventional techniques. Here we present two mouse models in which the function of striatonigral or striatopallidal neurons is selectively disrupted due to cell type-specific deletion of the striatal signaling protein dopamine- and cAMP-regulated phosphoprotein Mr 32kDa (DARPP-32). Using these mice, we found that the loss of DARPP-32 in striatonigral neurons decreased basal and cocaine-induced locomotion and abolished dyskinetic behaviors in response to the Parkinson's disease drug L-DOPA. Conversely, the loss of DARPP-32 in striatopallidal neurons produced a robust increase in locomotor activity and a strongly reduced cataleptic response to the antipsychotic drug haloperidol. These findings provide insight into the selective contributions of the direct and indirect pathways to striatal motor behaviors.


Assuntos
Corpo Estriado/metabolismo , Fosfoproteína 32 Regulada por cAMP e Dopamina/fisiologia , Atividade Motora/fisiologia , Neurônios/metabolismo , Animais , Catalepsia/induzido quimicamente , Catalepsia/fisiopatologia , Cocaína/farmacologia , Corpo Estriado/citologia , Dopaminérgicos/toxicidade , Inibidores da Captação de Dopamina/farmacologia , Fosfoproteína 32 Regulada por cAMP e Dopamina/genética , Fosfoproteína 32 Regulada por cAMP e Dopamina/metabolismo , Discinesia Induzida por Medicamentos/etiologia , Discinesia Induzida por Medicamentos/fisiopatologia , Feminino , Imunofluorescência , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Haloperidol/toxicidade , Imuno-Histoquímica , Levodopa/toxicidade , Potenciação de Longa Duração/fisiologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Transgênicos , Atividade Motora/efeitos dos fármacos , Plasticidade Neuronal/fisiologia , Neurônios/classificação , Neurônios/citologia , Potenciais Sinápticos/fisiologia
17.
Zh Vyssh Nerv Deiat Im I P Pavlova ; 63(4): 495-501, 2013.
Artigo em Russo | MEDLINE | ID: mdl-25464752

RESUMO

ASC mice, which were selected for high predisposition to catalepsy, are convenient genetic model for research of central mechanisms related to disorder of motor regulation. The aim of the work was to study the effect of glial cell line-derived neurotrophic factor (GDNF) on catalepsy, locomotor activity, stereotyping behavior in the marble burying test and on the dopamine level in striatum of ASC mice. It was shown that GDNF increased the locomotor activity in the open field, reduced catalepsy expression and stimulated the stereotyping obsessive-compulsive behavior. These changes in behavior were accompanied by increasing dopamine level in striatum.


Assuntos
Catalepsia/fisiopatologia , Predisposição Genética para Doença , Fator Neurotrófico Derivado de Linhagem de Célula Glial/biossíntese , Animais , Catalepsia/genética , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/metabolismo , Genótipo , Fator Neurotrófico Derivado de Linhagem de Célula Glial/genética , Humanos , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Atividade Motora/genética , Comportamento Estereotipado/efeitos dos fármacos , Comportamento Estereotipado/fisiologia
18.
Int J Neuropsychopharmacol ; 15(10): 1525-34, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22093169

RESUMO

Decreases in brain dopamine (DA) lead to catalepsy, quantified by the time a rat remains with its forepaws resting on a suspended horizontal bar. Low doses of the DA D2 receptor-preferring antagonist haloperidol repeatedly injected in a particular environment lead to gradual day-to-day increases in catalepsy (catalepsy sensitization) and subsequent testing following an injection of saline reveal conditioned catalepsy. We tested the hypothesis that D1-like and D2 receptors play different roles in catalepsy sensitization and in acquisition and expression of conditioned catalepsy. Rats were repeatedly treated with the DA D1-like receptor antagonist SCH 23990 (0.05, 0.1 and 0.25 mg/kg i.p.), the D2 receptor-preferring antagonist haloperidol (0.1, 0.25 and 0.5 mg/kg i.p.) or a combination of the two drugs and tested for catalepsy each day in the same environment. Following 10 drug treatment days, rats were injected with saline and tested for conditioned catalepsy in the previously drug-paired environment. Haloperidol did not elicit cataleptic responses in the initial session; however, rats developed sensitization with repeated testing. Significant catalepsy sensitization was not observed in rats repeatedly tested with SCH 23390. When rats were injected and tested with saline following haloperidol sensitization they exhibited conditioned catalepsy in the test environment; conditioned catalepsy was not seen following SCH 23390. Rats treated with 0.05 mg/kg SCH 23390+0.25 mg/kg haloperidol showed catalepsy sensitization but failed to show conditioned catalepsy. Conversely, SCH 23390 (0.05 mg/kg) given on the test day after sensitization to haloperidol (0.25 mg/kg) failed to block conditioned catalepsy. Repeated antagonism of D2 receptors leads to catalepsy sensitization with repeated testing in a specific environment. Conditioned catalepsy requires intact D1-like receptor function during sensitization sessions but not during test sessions. In conclusion, repeated antagonism of D2, but not D1-like receptors leads to catalepsy sensitization with repeated testing in a specific environment. Conditioned catalepsy requires functional D1-like receptors during sensitization sessions but not during test sessions.


Assuntos
Catalepsia/induzido quimicamente , Condicionamento Psicológico/fisiologia , Antagonistas de Dopamina/farmacologia , Haloperidol/farmacologia , Receptores de Dopamina D1/fisiologia , Animais , Catalepsia/fisiopatologia , Condicionamento Psicológico/efeitos dos fármacos , Antagonistas de Dopamina/toxicidade , Relação Dose-Resposta a Droga , Haloperidol/toxicidade , Masculino , Ratos , Ratos Wistar , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia , Receptores de Dopamina D1/antagonistas & inibidores
19.
Eksp Klin Farmakol ; 75(5): 3-6, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22834120

RESUMO

Stressing reduces the intensity of haloperidol-induced catalepsy in intact female rats and increases it in ovariectomized animals. Ovarioectomy reduces the severity of haloperidol catalepsy. Circadian rhythm acrophase of the cataleptogenic haloperidol activity in female rats after ovariectomy and stress exhibits significant displacement.


Assuntos
Antipsicóticos/farmacologia , Catalepsia/induzido quimicamente , Ritmo Circadiano/efeitos dos fármacos , Haloperidol/farmacologia , Estresse Fisiológico , Animais , Catalepsia/fisiopatologia , Feminino , Ovariectomia , Ratos , Ratos Wistar
20.
J Neurosci ; 30(8): 3146-55, 2010 Feb 24.
Artigo em Inglês | MEDLINE | ID: mdl-20181611

RESUMO

Fatty acid binding proteins (FABPs) are essential for energy production and long-chain polyunsaturated fatty acid-related signaling in the brain and other tissues. Of various FABPs, heart-type fatty acid binding protein (H-FABP, FABP3) is highly expressed in neurons of mature brain and plays a role in arachidonic acid incorporation into brain and heart cells. However, the precise function of H-FABP in brain remains unclear. We previously demonstrated that H-FABP is associated with the dopamine D(2) receptor long isoform (D2LR) in vitro. Here, we confirm that H-FABP binds to dopamine D(2) receptor (D2R) in brain extracts and colocalizes immunohistochemically with D2R in the dorsal striatum. We show that H-FABP is highly expressed in acetylcholinergic interneurons and terminals of glutamatergic neurons in the dorsal striatum of mouse brain but absent in dopamine neuron terminals and spines in the same region. H-FABP knock-out (KO) mice showed lower responsiveness to methamphetamine-induced sensitization and enhanced haloperidol-induced catalepsy compared with wild-type mice, indicative of D2R dysfunction. Consistent with the latter, aberrant increased acetylcholine (ACh) release and depolarization-induced glutamate (Glu) release were observed in the dorsal striatum of H-FABP KO mice. Furthermore, phosphorylation of CaMKII (Ca(2+)/calmodulin-dependent protein kinase II) and ERK (extracellular signal-regulated kinase) was significantly increased in the dorsal striatum. We confirmed elevated ERK phosphorylation following quinpirole-mediated D2R stimulation in H-FABP-overexpressing SHSY-5Y human neuroblastoma cells. Together, H-FABP is highly expressed in ACh interneurons and glutamatergic terminals, thereby regulating dopamine D2R function in the striatum.


Assuntos
Química Encefálica/fisiologia , Dopamina/metabolismo , Proteínas de Ligação a Ácido Graxo/metabolismo , Neostriado/metabolismo , Receptores de Dopamina D2/metabolismo , Transmissão Sináptica/fisiologia , Acetilcolina/metabolismo , Acetilcolina/farmacologia , Animais , Proteína Quinase Tipo 2 Dependente de Cálcio-Calmodulina/metabolismo , Catalepsia/induzido quimicamente , Catalepsia/metabolismo , Catalepsia/fisiopatologia , Linhagem Celular Tumoral , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Proteína 3 Ligante de Ácido Graxo , Proteínas de Ligação a Ácido Graxo/genética , Ácido Glutâmico/metabolismo , Haloperidol/farmacologia , Humanos , Imuno-Histoquímica , Interneurônios/citologia , Interneurônios/metabolismo , Ligantes , Metanfetamina/farmacologia , Camundongos , Camundongos Knockout , Fosforilação , Ligação Proteica/fisiologia , Receptores de Dopamina D2/genética
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa